& Chumbiauca, M
Over the past few years, the conversation around GLP-1 receptor agonists has been dominated by extremes: dramatic weight loss in clinical trials, before-and-after transformations on social media, and a public discourse that has oscillated between miracle and backlash
Journal of Clinical Gastroenterology, 56(8), 539 547
And looking ahead, Zydus ZYOG1 represents the direction the field is moving in: effective metabolic therapy in a more convenient oral form, pending stronger human trial data.
Cytoprotective Effects: Offering cell protection, it enhances cell resilience and longevity
The medication's pharmacokinetic profile supports once-weekly administration, with a half-life of approximately five days that allows for sustained therapeutic effects between doses